Edition:
India

Hutchison China MediTech Ltd (HCM.L)

HCM.L on London Stock Exchange

360.00GBp
11 Nov 2019
Change (% chg)

-- (--)
Prev Close
360.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
83,657
52-wk High
566.80
52-wk Low
260.50

Latest Key Developments (Source: Significant Developments)

Hutchison China MediTech, Innovent Expand Collaboration On Sintilimab & Surufatinib
Thursday, 10 Oct 2019 

Oct 10 (Reuters) - Hutchison China MediTech Ltd ::INNOVENT AND CHI-MED EXPAND GLOBAL COLLABORATION.INNOVENT AND CHI-MED EXPAND GLOBAL COLLABORATION TO EVALUATE COMBINATION OF SINTILIMAB AND SURUFATINIB IN SOLID TUMORS.EXPANSION TO ALLOW INNOVENT, CO TO EXPLORE POTENTIAL APPLICATION OF TYVYT, SURUFATINIB COMBINATION THERAPY IN SOLID TUMORS.EXISTING COLLABORATION WITH INNOVENT ON FRUQUINTINIB IS PROGRESSING WELL.CLINICAL STUDIES WITH NEW COMBINATION WILL BE CONDUCTED BOTH IN UNITED STATES AND IN CHINA..  Full Article

Hutchison China MediTech Initiates Phase I/IB Trial of HMPL-523 in Lymphoma
Friday, 4 Oct 2019 

Oct 4 (Reuters) - Hutchison China MediTech Ltd ::CHI-MED INITIATES AN INTERNATIONAL PHASE I/IB TRIAL OF HMPL-523 IN PATIENTS WITH ADVANCED RELAPSED OR REFRACTORY LYMPHOMA.  Full Article

Hutchison China Meditech Says CK Hutchison To Sell 1.3% Stake At $17.65 Per ADR
Monday, 30 Sep 2019 

Sept 30 (Reuters) - CK Hutchison Holdings Ltd <0001.HK>::CK HUTCHISON PRICED AN OFFERING TO SELL 1.3% OF TOTAL SHARE CAPITAL IN CHI-MED THROUGH UNDERWRITTEN PUBLIC OFFERING.CK HUTCHISON STAKE SALE IN CHI-MED THROUGH UNDERWRITTEN PUBLIC OFFERING WOULD REDUCE ITS STAKE IN CO FROM 51.1% TO 49.9%.OFFERING PRICE WAS US$17.65 PER AMERICAN DEPOSITARY SHARE, EACH ADS REPRESENTS FIVE ORDINARY SHARES, PAR VALUE US$0.10.CK HUTCHISON PLANS TO MAINTAIN ITS SHAREHOLDING IN CHI-MED AS A STRATEGIC INVESTMENT FOR LONG TERM.  Full Article

The Capital Group Companies Discloses 5.0357% Stake In Hutchison China Meditech As Of Aug 15 - Filing
Tuesday, 20 Aug 2019 

Aug 20 (Reuters) - Hutchison China MediTech Ltd ::THE CAPITAL GROUP COMPANIES, INC. DISCLOSES 5.0357% STAKE IN HUTCHISON CHINA MEDITECH LTD AS OF AUG 15 - FILING.  Full Article

Hutchison China Meditech Says Hutchison Healthcare Holdings Ltd Intends To Offer 8.5 Mln ADSS Of Co
Friday, 28 Jun 2019 

June 27 (Reuters) - Hutchison China MediTech Ltd ::HUTCHISON CHINA MEDITECH LTD - HUTCHISON HEALTHCARE HOLDINGS LIMITED INTENDS TO OFFER 8.5 MILLION AMERICAN DEPOSITARY SHARES OF CO - SEC FILING.  Full Article

Chi-Med Announces Amendment To 2013 License & Collaboration Agreement On Fruquintinib With Eli Lilly And Co
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - :CHI-MED ANNOUNCES AMENDMENT TO 2013 LICENSE & COLLABORATION AGREEMENT ON FRUQUINTINIB WITH ELI LILLY AND COMPANY.HUTCHISON CHINA -2018 AMENDMENT NOW GIVES CO ALL PLANNING, EXECUTION, DECISION MAKING RESPONSIBILITIES FOR LCI DEVELOPMENT ON FRUQUINTINIB IN CHINA.HUTCHISON CHINA - UPDATED GUIDANCE FOR 2018 INCLUDES A $12 MILLION INCREASE IN EXPECTED FULL YEAR INNOVATION PLATFORM RESEARCH AND DEVELOPMENT EXPENSE TO $142-152 MILLION.HUTCHISON CHINA -TO ASSUME ALL DEVELOPMENT COSTS OF LIFE CYCLE INDICATIONS IN CHINA IN RETURN FOR INCREASE IN BOTH MILESTONE AND ROYALTY PAYMENTS FROM LILLY.HUTCHISON CHINA -CO TERRITORY WILL EXPAND TO PROVINCES THAT REPRESENT 40% OF SALES OF FRUQUINTINIB IN CHINA SUBJECT TO ADDITIONAL CRITERIA BEING MET.HUTCHISON CHINA MEDITECH -LILLY WILL PAY CHI-MED A FEE FOR SERVICE TO CONDUCT ALL PROMOTIONAL ACTIVITIES IN CHI-MED TERRITORY.  Full Article

Hutchison China MediTech Says Phase III Results For Fruquintinib Did Not Meet Primary Endpoint
Friday, 16 Nov 2018 

Nov 16 (Reuters) - Hutchison China MediTech Ltd ::HUTCHISON CHINA MEDITECH - ANNOUNCES PHASE III FALUCA TRIAL RESULTS FOR FRUQUINTINIB IN THIRD-LINE, ADVANCED NON-SMALL CELL LUNG CANCER IN CHINA.TRIAL DID NOT MEET PRIMARY ENDPOINT OF OVERALL SURVIVAL DESPITE IMPROVEMENT IN PROGRESSION-FREE SURVIVAL.FULL DETAILED RESULTS ARE EXPECTED TO BE DISCLOSED AT AN UPCOMING SCIENTIFIC MEETING.  Full Article

Hutchison China MediTech Says HY Group Rev Falls To $102.2 Mln
Friday, 27 Jul 2018 

July 27 (Reuters) - Hutchison China MediTech Ltd ::2018 INTERIM RESULTS AND CLINICAL PROGRAMS UPDATE.HY GROUP REVENUE OF $102.2 MILLION VS $126.6 MLN .HY TOTAL CONSOLIDATED SALES FOR COMMERCIAL PLATFORM FELL 15 PCT TO $88.6 MILLION VS $103.9 MLN .HY NET LOSS ATTRIBUTABLE TO CHI‑MED OF $32.7 MILLION VS NET PROFIT $1.7 MLN LAST YEAR.CASH RESOURCES OF $416.9 MILLION AT GROUP LEVEL AS OF JUNE 30, 2018.$20 MILLION INCREASE IN EXPECTED FULL YEAR INNOVATION PLATFORM RESEARCH AND DEVELOPMENT EXPENSE TO $130-140 MILLION.  Full Article